Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016
September 22 2016 - 07:00AM
Business Wire
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH /TSX:AUP), a clinical
stage biopharmaceutical company focused on the global immunology
market, today announced that its Chief Executive Officer, Charles
Rowland, will participate in a Fireside Chat at the Leerink
Partners Roundtable Series: Rare Disease and Immuno-Oncology on
September 28, 2016 at 11:05am ET in New York. To access the live
webcast, please visit the investor section of the Aurinia website.
A replay will also be archived on the site following the event.
About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on
developing and commercializing therapies to treat targeted patient
populations that are suffering from serious diseases with a high
unmet medical need. The company is currently developing
voclosporin, an investigational drug, for the treatment of lupus
nephritis (LN). The company is headquartered in Victoria, BC and
focuses its development efforts globally. www.auriniapharma.com
About Voclosporin
Voclosporin, an investigational drug, is a novel and potentially
best-in-class calcineurin inhibitor (“CNI”) with clinical data in
over 2,000 patients in other indications. Voclosporin is an
immunosuppressant, with a synergistic and dual mechanism of action
that has the potential to improve near- and long-term outcomes in
LN when added to standard of care (MMF). By inhibiting calcineurin,
voclosporin blocks IL-2 expression and T-cell mediated immune
responses. It is made by a modification of a single amino acid of
the cyclosporine molecule which has shown a more predictable
pharmacokinetic and pharmacodynamic relationship, an increase in
potency, an altered metabolic profile, and potential for flat
dosing. The Company anticipates that upon regulatory approval,
patent protection for voclosporin will be extended in the United
States and certain other major markets, including Europe and Japan,
until at least October 2027 under the Hatch-Waxman Act and
comparable laws in other countries.
About Lupus Nephritis (LN)
Lupus Nephritis (LN) in an inflammation of the kidney caused by
Systemic Lupus Erythematosus (SLE) and represents a serious
progression of SLE. SLE is a chronic, complex and often disabling
disorder and affects more than 500,000 people in the United States
(mostly women). The disease is highly heterogeneous, affecting a
wide range of organs & tissue systems. It is estimated that as
many as 60% of all SLE patients have clinical LN requiring
treatment. Unlike SLE, LN has straightforward disease outcomes
where an early response correlates with long-term outcomes,
measured by proteinuria. In patients with LN, renal damage results
in proteinuria and/or hematuria and a decrease in renal function as
evidenced by reduced estimated glomerular filtration rate (eGFR),
and increased serum creatinine levels. LN is debilitating and
costly and if poorly controlled, LN can lead to permanent and
irreversible tissue damage within the kidney, resulting in
end-stage renal disease (ESRD), thus making LN a serious and
potentially life-threatening condition.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160922005293/en/
Investor & Media:Celia EconomidesAssociate VP,
Investor Relationsceconomides@auriniapharma.com